Richard Z. Cheng

Dr. Richard Z. Cheng

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

14 January 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
William B. GrantWilliam B. Grant
William B. Grant
Sunil J. WimalawansaSunil J. Wimalawansa
Sunil J. Wimalawansa
Pawel PludowskiPawel Pludowski
Pawel Pludowski
RCRichard Z. Cheng
Richard Z. Cheng
Vitamin D offers numerous under-recognized health benefits beyond its well-known role in musculoskeletal health. It is vital for extra-renal tissues, prenatal health, brain function, immunity, pregnancy, cancer prevention, and cardiovascular health. Existing guidelines issued by governmental and health organizations are bone-centric and largely overlook the abovementioned extra-skeletal benefits and optimal thresholds for vitamin D. In addition, they rely on randomized controlled trials (RCTs), which seldom show benefits due to high baseline 25-hydroxyvitamin D [25(OH)D] concentrations, moderate supplementation doses, and flawed study designs. This review emphasizes the findings from prospective cohort studies showing that higher 25(OH)D concentrations reduce the risks of major diseases and mortality, including pregnancy and birth outcomes. Serum concentrations > 30 ng/mL (75 nmol/L) significantly lower disease and mortality risks compared to <20 ng/mL. With 25% of the U.S. population and 60% of Central Europeans having levels <20 ng/mL, concentrations should be raised above 30 ng/mL. This is achievable through daily supplementation with 2000 IU/day (50 mcg/day) of vitamin D3, which prevent diseases and deaths. Furthermore, a daily dose between 4000 and 6000 IU of vitamin D3 to achieve serum 25(OH)D levels between 40 and 70 ng/mL would provide greater protection against many adverse health outcomes. Future guidelines and recommendations should integrate the findings from observational prospective cohort studies and well-designed RCTs to improve public health and personalized care.

25 June 2025 in Nutrients
Verified
Journal Article
Open access
PDF file
William B. GrantWilliam B. Grant
William B. Grant
BCBarbara Joan Boucher [ms Cohen]
Barbara Joan Boucher [ms Cohen]
RCRichard Z. Cheng
Richard Z. Cheng
Pawel PludowskiPawel Pludowski
Pawel Pludowski
Sunil J. WimalawansaSunil J. Wimalawansa
Sunil J. Wimalawansa
The role of vitamin D in reducing cardiovascular disease (CVD) risk remains debated despite growing evidence. Prospective observational studies consistently show that low serum 25-hydroxyvitamin D [25(OH)D] concentrations (below 40–50 nmol/L [16–20 ng/mL]) are associated with the highest risk of CVD incidence. In addition, a large prospective observational study found that serum 25(OH)D concentration was inversely correlated with CVD mortality rate to over 100 nmol/L. Randomized controlled trials have not generally demonstrated benefit due to faulty study designs, such as enrolling participants with baseline 25(OH)D levels > 50 nmol/L. However, a major trial found that 60,000 IU/month of vitamin D3 supplementation reduced the risk of major cardiovascular events for participants with predicted 25(OH)D concentrations ≥ 50 nmol/L or taking statins or CV drugs by ~13 to ~17%. In addition, vitamin D supplementation studies have found modest reductions in several CVD risk factors. Other observational studies of vitamin D supplementation have reported reduced CVD risks (e.g., ischemic heart disease, hypertension, and myocardial infarction). Temporal ecological studies further support this relationship, revealing that CVD incidence rates are lowest in summer and CVD mortality rates are significantly higher in late winter—when 25(OH)D concentrations are lowest—compared to late summer. A previously reported analysis using eight of Hill’s criteria for causality in a biological system further strengthens the biological plausibility of vitamin D’s role in CVD risk reduction. Its role in modulating inflammation and oxidative stress, improving endothelial function, and reducing several cardiometabolic risk factors supports its inclusion as part of a comprehensive, multi-modal approach to cardiovascular health. Therefore, vitamin D should be considered an integral component in the prevention and management of CVD. Preferably, it should be used in combination with other nutritional supplements, a heart-healthy diet, and prescription medications to reduce the risk of CVD incidence. People should consider vitamin D3 supplementation with at least 2000 IU/day (50 mcg/day) (more for those who are obese) when sun exposure is insufficient to maintain serum 25(OH)D concentrations above 75 nmol/L. To reduce CVD mortality rates, higher doses to achieve higher 25(OH)D concentrations might be warranted.

10 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
RCRichard Z. Cheng
Richard Z. Cheng
Background/Objectives: Despite decades of focus on the Somatic Mutation Theory (SMT), survival outcomes for cancer remain modest, with most therapies offering only marginal benefits. Mounting evidence suggests that mitochondrial dysfunction, rather than random mutations, represents the central initiating event in carcinogenesis. Methods: We applied a systems-based Root Cause Analysis (RCA) framework, adapted from engineering and healthcare, to trace modifiable upstream biological drivers of mitochondrial collapse. Literature spanning environmental, nutritional, metabolic, infectious, and hormonal domains was reviewed to identify initiating contributors. Results: We propose a three-layer model of cancer initiation: (1) upstream initiating drivers (toxins, nutrient deficiencies, chronic infections, hormonal disruption, psychosocial stress, and iatrogenic factors); (2) central bioenergetic collapse via mitochondrial dysfunction, oxidative stress, and metabolic instability; and (3) downstream oncogenic phenotype, encompassing genomic instability, inflammation, immune evasion, and tumor progression. RCA organizes these drivers into a coherent sequence, highlighting prevention and intervention leverage points.

22 September 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
RCRichard Z. Cheng
Richard Z. Cheng
Environmental and dietary exposures contribute to the modern burden of cancer, atherosclerotic cardiovascular disease (ASCVD), and type 2 diabetes mellitus (T2DM). While mutagenesis remains central to carcinogenesis, many exposures impair mitochondrial function—disrupting electron transport, depolarizing membranes, damaging mitochondrial DNA, and amplifying reactive oxygen species. These mitochondrial injuries converge on oxidative stress, chronic inflammation, endothelial dysfunction, and insulin resistance, thereby linking diverse hazards (industrial solvents, pesticides, heavy metals, air pollution) and dietary patterns (ultra-processed foods, high glycemic load) to common chronic diseases. This narrative review synthesizes human epidemiology with mechanistic evidence to map exposures → mitochondrial injury → disease end points, grading the strength of evidence and distinguishing hazard from risk. We highlight robust associations (e.g., benzene–leukemia, PM2.5–ASCVD, cadmium–CVD/T2DM) and areas of uncertainty (e.g., EMF, omega-6 oils). By centering mitochondria, we offer a unifying framework for prevention policy and clinical practice, and outline research priorities for exposomic measurement, mitochondrial biomarkers, and intervention trials.

3 February 2026 in Preprints.org
Verified
Preprint
Open access
PDF file
RCRichard Z. Cheng
Richard Z. Cheng
Systemic Leaky Barrier Syndrome (SLBS) is a conceptual framework in which loss of integrity across multiple biological barriers — intestinal, vascular, blood–brain, pulmonary, renal, and skin — is driven by shared structural, metabolic, and inflammatory mechanisms. This hypothesis unifies disparate chronic diseases and aging processes by focusing on common upstream drivers (oxidative stress, micronutrient insufficiency, mitochondrial dysfunction, and chronic inflammation) that impair tight junctions and cell–matrix adhesion across tissues. SLBS reframes chronic disease not as isolated organ dysfunction, but as systemic failure of barrier integrity, with clinical implications for early detection, prevention, and integrative therapeutic strategies. This framework also has implications for cancer progression, where invasion and metastasis require coordinated failure of multiple host barrier systems.